Enliven Therapeutics (ELVN) Projected to Release Quarterly Earnings on Wednesday

Posted by Geri Gentry on Nov 4th, 2026

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) is projected to issue its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Enliven Therapeutics to post earnings of ($0.4479) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts expect Enliven Therapeutics to post ($1.79) EPS for the current fiscal year and ($2.26) EPS for the next fiscal year.

Enliven Therapeutics Price Performance

ELVN stock opened at $44.83 on Wednesday. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $62.32. The company’s 50 day moving average is $48.07 and its two-hundred day moving average is $42.76.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ELVN shares. Mizuho increased their target price on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Morgan Stanley initiated coverage on shares of Enliven Therapeutics in a research report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target for the company. Guggenheim restated a “buy” rating on shares of Enliven Therapeutics in a research note on Thursday, October 8th. William Blair initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $75.44.

Get Our Latest Stock Report on Enliven Therapeutics

Insider Buying and Selling

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the completion of the sale, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. This represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 31,054 shares of company stock valued at $1,493,823. 3.00% of the stock is owned by company insiders.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.